New Jersey-based development-stage biopharmaceutical company Silo Pharma has secured USD 2 million via a registered direct offering consisting of 0.9 million common shares at USD 2.18 per share. Concurrently, the company issued 0.9 million warrants at an exercise price of USD 2.06 per share via a private placement. The offering is expected to close on June 6, 2024.
The net proceeds are expected to be used for working capital and general corporate purposes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.